Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target hoisted by analysts at Stifel Nicolaus from $200.00 to $207.00 in a report issued on Friday,Benzinga reports. The firm presently has a "buy" rating on the biotechnology company's stock. Stifel Nicolaus' price target would suggest a potential upside of 63.62% from the stock's current price.

A number of other research firms also recently commented on ASND. The Goldman Sachs Group increased their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a "buy" rating in a research report on Tuesday, September 17th. TD Cowen raised their price objective on shares of Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Evercore ISI raised their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 17th. Wedbush restated an "outperform" rating and issued a $181.00 target price on shares of Ascendis Pharma A/S in a research note on Friday. Finally, Oppenheimer restated an "outperform" rating and issued a $190.00 target price (up previously from $180.00) on shares of Ascendis Pharma A/S in a research note on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $191.77.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND traded up $2.23 during trading hours on Friday, reaching $126.51. The stock had a trading volume of 1,448,850 shares, compared to its average volume of 450,130. Ascendis Pharma A/S has a 1 year low of $90.13 and a 1 year high of $161.00. The firm's 50 day moving average is $132.15 and its 200-day moving average is $132.80. The stock has a market capitalization of $7.67 billion, a price-to-earnings ratio of -13.95 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analysts' expectations of $94.74 million. Analysts forecast that Ascendis Pharma A/S will post -7.35 EPS for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Hedge funds have recently added to or reduced their stakes in the business. Signaturefd LLC grew its holdings in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock worth $102,000 after buying an additional 80 shares in the last quarter. Profund Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 3.0% during the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company's stock worth $398,000 after buying an additional 85 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company's stock worth $209,000 after buying an additional 143 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Ascendis Pharma A/S by 0.3% during the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company's stock worth $11,717,000 after buying an additional 228 shares in the last quarter. Finally, Avior Wealth Management LLC grew its holdings in Ascendis Pharma A/S by 3.0% in the third quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company's stock valued at $1,226,000 after purchasing an additional 240 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.